Sudhathi Chennuru, MD
Hematology & Oncology · Kettering, OHNPI 1689740326
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $918 of the $1,076 with a category attached, or 85.3%. It is spread thinly across 22 manufacturers, the largest accounting for just 11.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $463 and has fallen 89.4% since, to $49 in 2025. That places this record below the midpoint for hematology & oncology clinicians in OH, where the typical reported total is $2,354.
Across 47 payments — averaging $22.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$128
- Sanofi$112
- Merck$111
- Exelixis Inc.$80
- Gilead$75
- Seagen Inc.$64
- plus $505 from 16 others
Across 1 payment — averaging $14,532 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$15K
What the payments were for
- Food & beverage$91885%
- Education$15815%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 5 | $128 |
| Sanofi | 4 | $112 |
| Merck | 5 | $111 |
| Exelixis Inc. | 3 | $80 |
| Gilead(2 entities) | 4 | $75 |
| Seagen Inc. | 3 | $64 |
| Amgen | 3 | $55 |
| Johnson & Johnson | 2 | $47 |
| AstraZeneca | 2 | $42 |
| Taiho Oncology, Inc. | 2 | $41 |
| Eisai Inc. | 2 | $40 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $34 |
| Regeneron Healthcare Solutions, Inc. | 1 | $33 |
| Genmab U.S., Inc. | 1 | $33 |
| Bristol Myers Squibb | 1 | $27 |
| Pfizer | 2 | $26 |
| Jazz Pharmaceuticals Inc. | 1 | $25 |
| Sumitomo Pharma America, Inc. | 1 | $25 |
| Myovant Sciences Inc. | 1 | $24 |
| Sobi, Inc | 1 | $23 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Pharming Healthcare, Inc. | 1 | $14 |
How this compares
$1,076 in reported general payments places this provider in the 35th percentile of 450 hematology & oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TasignaNilotinib Hcl | 25 | $443,118 |
| DopteletAvatrombopag Maleate | 18 | $282,283 |
| Lenalidomide | 14 | $244,509 |
| JakafiRuxolitinib Phosphate | 14 | $242,028 |
| LenvimaLenvatinib Mesylate | 11 | $238,888 |
| PromactaEltrombopag Olamine | 15 | $206,181 |
| ImbruvicaIbrutinib | 12 | $196,053 |
| CalquenceAcalabrutinib Maleate | 13 | $185,651 |
| XareltoRivaroxaban | 19 | $16,494 |
| EliquisApixaban | 24 | $13,490 |
| Fentanyl | 11 | $1,029 |
| Anastrozole | 88 | $1,000 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 26 | $875 |
| Acyclovir | 33 | $701 |
| Hydroxyurea | 25 | $521 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisTasigna, Promacta | $128 | $649,29940 claims |
| Eisai Inc.Lenvima | $40 | $238,88811 claims |
| AstraZenecaCalquence | $42 | $185,65113 claims |
| Johnson & JohnsonXarelto | $47 | $16,49419 claims |
| PfizerEliquis | $26 | $13,49024 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 450 hematology & oncology providers in Ohio.
Other hematology & oncology in Kettering
- Alejandro CalvoKettering$463K
- Satheesh KathulaKettering$297K
- Tarek SabaghKettering$162K
- Hillard LazarusCleveland$2M
- Kasra KaramlouSandusky$1.8M
- David WaterhouseCincinnati$1.3M
- Taral PatelColumbus$888K
- Tarek ChidiacColumbus$765K
- Saulius GirniusMontgomery$707K
- Ronald BukowskiCleveland$594K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.